Investment Decisions shall be driven by thorough analyses that integrate

• all commercial aspects including a drug’s current and future competitive environment as well as pharmacoeconomics (also see > Commercial Assessment),
• the analysis and mitigation of development risk (also see > R&D Productivity Increase),
• the identification of a company’s cost of capital,
• the calculation of expected (‘risk-adjusted’) net present values (‘eNPVs’),
• the assessment how value is expected to increase once defined milestones have been reached,
• ‘comparables’, i.e. market transactions with a known value.

Bioscience Valuation supports management with comprehensive analyses and clear investment recommendations that can be shared with any stakeholder.